Abstract: The article discusses the research and potential implementation of Psychedelic-Assisted Therapy (PAT) in the Veterans Health Administration (VA). It highlights the growing evidence supporting PATs with MDMA and psilocybin for conditions like PTSD and depression, designated as breakthrough therapies by the FDA. The VA aims to strategically plan for potential future clinical use of PATs to provide timely and safe access to novel treatments for veterans. The article also emphasizes the importance of partnerships, collaborations, and strategic planning to optimize the delivery of emerging treatment modalities for veterans.